Major Shoulder or Elbow Joint Procedures with CC/MCC DRG Reimbursement

DRG 507 encompasses major shoulder or elbow joint procedures performed with Complication or Comorbidity or Major Complication or Comorbidity, capturing higher-complexity inpatient orthopedic surgeries. It matters for inpatient reimbursement because the assigned Diagnosis-Related Group reflects increased expected resource use and drives Medicare payment levels for these complex cases.

DRG 507 Overview

DRG 507 covers major shoulder or elbow joint procedures performed with the presence of a Complication or Comorbidity or a Major Complication or Comorbidity, including complex arthroplasty, revision, or extensive reconstructive operations. It groups inpatient stays where surgical complexity and coexisting conditions increase resource use and length of stay. This Diagnosis-Related Group matters for Medicare payment because cases assigned here typically trigger higher reimbursement relative to less complex joint procedure groups due to increased expected costs. Accurate coding of comorbidities and procedure detail directly affects grouping and payment.

Acute perioperative optimization and complication reduction trials: these studies evaluate interventions delivered during the index hospitalization for major shoulder or elbow joint procedures (e.g., perioperative blood management strategies, enhanced anesthesia protocols, infection prevention bundles, and VTE prophylaxis regimens). They typically enroll adults undergoing complex arthroplasty or revision shoulder/elbow surgery, often including patients with significant comorbidities (the CC/MCC population), and measure short-term outcomes such as intraoperative blood loss, surgical-site infection rates, length of stay, and 30-day readmission. Findings are directly relevant to inpatient teams and payers because reducing complications and LOS drives DRG resource use, impacts reimbursement risk, and informs best practices for high-cost surgical admissions.
Comparative effectiveness and device/technique trials: these randomized or pragmatic studies compare surgical approaches, implant types, fixation methods, or rehabilitation initiation strategies for major shoulder or elbow joint procedures (for example, reverse versus anatomic shoulder arthroplasty techniques or minimally invasive versus standard exposure in complex elbow reconstruction). They enroll patients across functional levels and comorbidity burden to determine differences in early postoperative recovery, implant survival proxies, complication profiles, and early resource utilization within the hospitalization and up to 90 days. Results guide surgeons and hospital administrators on which approaches reduce index admission complications and downstream costs, informing formulary/device adoption decisions and value-based procurement relevant to DRG payments.
Post-discharge recovery, functional outcomes, and utilization studies: these prospective cohort or interventional trials focus on the transition from inpatient to home or rehab for patients with major shoulder/elbow procedures and CC/MCCs, assessing early rehabilitation models, tele-rehabilitation, coordination with post-acute care, and predictors of readmission or prolonged post-acute utilization. They study heterogeneous patients at higher risk for poor recovery due to age, frailty, or comorbid conditions, measuring functional scores, return-to-activity timelines, post-acute facility days, and 30–90 day healthcare utilization. Insights help payers and providers design discharge pathways, allocate post-acute resources, and target interventions that minimize costly readmissions and optimize total episode-of-care spending under DRG-based payment models.

Acute perioperative optimization and complication reduction trials: these studies evaluate interventions delivered during the index hospitalization for major shoulder or elbow joint procedures (e.g., perioperative blood management strategies, enhanced anesthesia protocols, infection prevention bundles, and VTE prophylaxis regimens). They typically enroll adults undergoing complex arthroplasty or revision shoulder/elbow surgery, often including patients with significant comorbidities (the CC/MCC population), and measure short-term outcomes such as intraoperative blood loss, surgical-site infection rates, length of stay, and 30-day readmission. Findings are directly relevant to inpatient teams and payers because reducing complications and LOS drives DRG resource use, impacts reimbursement risk, and informs best practices for high-cost surgical admissions.
Comparative effectiveness and device/technique trials: these randomized or pragmatic studies compare surgical approaches, implant types, fixation methods, or rehabilitation initiation strategies for major shoulder or elbow joint procedures (for example, reverse versus anatomic shoulder arthroplasty techniques or minimally invasive versus standard exposure in complex elbow reconstruction). They enroll patients across functional levels and comorbidity burden to determine differences in early postoperative recovery, implant survival proxies, complication profiles, and early resource utilization within the hospitalization and up to 90 days. Results guide surgeons and hospital administrators on which approaches reduce index admission complications and downstream costs, informing formulary/device adoption decisions and value-based procurement relevant to DRG payments.
Post-discharge recovery, functional outcomes, and utilization studies: these prospective cohort or interventional trials focus on the transition from inpatient to home or rehab for patients with major shoulder/elbow procedures and CC/MCCs, assessing early rehabilitation models, tele-rehabilitation, coordination with post-acute care, and predictors of readmission or prolonged post-acute utilization. They study heterogeneous patients at higher risk for poor recovery due to age, frailty, or comorbid conditions, measuring functional scores, return-to-activity timelines, post-acute facility days, and 30–90 day healthcare utilization. Insights help payers and providers design discharge pathways, allocate post-acute resources, and target interventions that minimize costly readmissions and optimize total episode-of-care spending under DRG-based payment models.

OpenPayer

Summary & Overview

Major Shoulder or Elbow Joint Procedures with CC/MCC: Inpatient Reimbursement Overview

DRG 507 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes